# Efficacy of VIUSID® Plus GLIZIGEN® in Patients With Papilloma Virus Esophageal

> **NCT03584308** · PHASE2 · COMPLETED · sponsor: **Catalysis SL** · enrollment: 110 (actual)

## Conditions studied

- Papilloma Viral Infection
- Papillomavirus Infections
- Esophageal Viral Wart
- Esophageal Verrucous Carcinoma

## Interventions

- **DIETARY_SUPPLEMENT:** Viusid®
- **DIETARY_SUPPLEMENT:** Glizigen®
- **DIETARY_SUPPLEMENT:** Viusid Placebo
- **DIETARY_SUPPLEMENT:** Glizigen Placebo

## Key facts

- **NCT ID:** NCT03584308
- **Lead sponsor:** Catalysis SL
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-10-15
- **Primary completion:** 2018-05-15
- **Final completion:** 2018-12-15
- **Target enrollment:** 110 (ACTUAL)
- **Last updated:** 2019-05-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03584308

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03584308, "Efficacy of VIUSID® Plus GLIZIGEN® in Patients With Papilloma Virus Esophageal". Retrieved via AI Analytics 2026-07-08 from https://api.ai-analytics.org/clinical/NCT03584308. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*